Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14087 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Filippo Antonio Canale und 14 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Transplantation and Cellular Therapies Unit, Grande Ospedale Metropolitano, "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Relapsed or refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) still represent an unmet clinical need despite the new immune therapies available for these patients. We report the case of a Ph + ALL relapsed one year after allogeneic stem cell transplant. After one DLI was started CAR‐T program with brexucabtageneautoleucel, using as bridging treatment ponatinib, vincristine and prednisone. Brexu‐cel infusion was performed in 2023, without CRS or ICANS onset. One month after Brexu‐cel infusion BM aspirate and CT‐PET showed recovery of full donor chimerism, MRD negativity and complete metabolic remission. Subsequently was started maintenance with ponatinib: at last follow‐up, the patient persisted in leukemia‐free status. CAR‐T cells represent the most powerful treatment for r/r Ph + ALL but there is no consensus about the optimal bridging strategy and also regarding the management algorithm during “post CAR‐T phase”. Here, we report the efficacy of ponatinib as a bridge to anti‐CD19 CAR‐T cell therapy and as post CAR‐T maintenance. Our experience suggests that a preserving approach with TKI associated to low‐dose chemotherapy can be the optimal bridging therapy prior to CAR‐T and that an “MRD‐guided” and “TKI‐based” maintenance strategy can represent the best choice for Ph + ALL which satisfactorily responds to CAR‐T.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Transplantation and Cellular Therapies Unit, Grande Ospedale Metropolitano, "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
- Stem Cell Transplantation Program CIC 587, Grande Ospedale Metropolitano, "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
- Hematology Unit, Grande Ospedale Metropolitano, "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
ORCID-Profile: Martina Pitea
Zitieren
APA
Canale, F. A., Pitea, M., Alati, C., Porto, G., Pratico, G., Utano, G., Germanò, J., Imbalzano, L., Ferreri, A., Verduci, C., Santoro, L., Policastro, G., Loteta, B., Pugliese, M., & Martino, M. (2024). Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14087
Vancouver
Canale FA, Pitea M, Alati C, Porto G, Pratico G, Utano G, et al. Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. European Journal of Haematology. 2024. doi:10.1111/ejh.14087
BibTeX
@article{Canale2024,
author = {Canale, Filippo Antonio and Pitea, Martina and Alati, Caterina and Porto, Gaetana and Pratico, Giulia and Utano, Giovanna and Germanò, Jessyca and Imbalzano, Lucrezia and Ferreri, Anna and Verduci, Chiara and Santoro, Ludovica and Policastro, Giorgia and Loteta, Barbara and Pugliese, Marta and Martino, Massimo},
title = {Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14087}
}
EUVIMED